David B. Wells, listed as an insider at Hims & Hers Health, bought 48,400 shares on the open market on May 26, 2026, paying $24.24 per share for a total of about $1.17 million. A purchase of this size is notable because insiders already have exposure to the company through their roles, so buying additional shares with personal funds can be a meaningful signal of commitment. Insider trades matter most when they come from people close to the business, since they may have a clearer view of operations and strategy than outside investors (while still being restricted from trading on non-public information). Wells is not identified here as a CEO or CFO, but as an “insider,” which typically includes executives, directors, or large shareholders who must report their trades. This buy also stands out against recent insider activity: within the last 30 days, CFO Oluyemi Okupe reported a sale of roughly $188,000 on May 18, following additional selling in April and May. Mixed activity like this is common—sales can occur for many personal reasons—so the key takeaway is that Wells’ sizable purchase adds a counterpoint to the recent executive selling and is worth tracking for follow-on filings.